

E Michael Lewiecki

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8151558/e-michael-lewiecki-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

249
papers

13,592
citations

59
h-index

111
g-index

294
ext. papers

16,157
ext. citations

4.9
avg, IF

6.71
L-index

#	Paper	IF	Citations
249	Evaluating Patients for Secondary Causes of Osteoporosis.. <i>Current Osteoporosis Reports</i> , 2022 , 20, 1	5.4	0
248	Glucocorticoid-Induced Osteoporosis 2022 , 285-290		
247	Romosozumab and antiresorptive treatment: the importance of treatment sequence.. <i>Osteoporosis International</i> , 2022 , 1	5.3	2
246	Racial Disparities and Inequalities in the Management of Patients With Osteoporosis.. <i>Orthopaedic Nursing</i> , 2022 , 41, 125-134	0.9	0
245	Osteoporosis Treatment Success and Failure 2021 , 185-195		
244	Osteoporosis Management with Focus on Spine 2021 , 61-92		
243	Operationalizing Treat-to-Target for Osteoporosis. <i>Endocrinology and Metabolism</i> , 2021 , 36, 270-278	3.5	2
242	American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. <i>Endocrine Practice</i> , 2021 , 27, 379-380	3.2	8
241	Assessment of Skeletal Strength: Bone Density Testing and Beyond. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021 , 50, 299-317	5.5	1
240	Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries. <i>BMJ Open</i> , 2021 , 11, e047258	3	4
239	Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. <i>Journal of Clinical Densitometry</i> , 2021 , 24, 3-13	3.5	18
238	Pulse-echo Ultrasound Identifies Caucasian and Hispanic Women at Risk for Osteoporosis. <i>Journal of Clinical Densitometry</i> , 2021 , 24, 175-182	3.5	3
237	Effective communication regarding risk of fracture for individuals at risk of fragility fracture: a scoping review. <i>Osteoporosis International</i> , 2021 , 1	5.3	2
236	Teriparatide: Label changes and identifying patients for long-term use. <i>Cleveland Clinic Journal of Medicine</i> , 2021 , 88, 489-493	2.8	2
235	Evaluation of the osteoporosis patient 2021 , 1475-1500		2
234	Letter to the Editor from Dreyer, et al: "Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e1920-e1921	5.6	
233	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. <i>Endocrine Practice</i> , 2020 , 26, 1-46	3.2	164

232	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1784-1802	4.7	5
231	The Rare Bone Disease TeleECHO Program: Leveraging Telehealth to Improve Rare Bone Disease Care. <i>Current Osteoporosis Reports</i> , 2020 , 18, 344-349	5.4	3
230	Estimation of Long-Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX- and Virtual Twin-Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials. <i>JBMR Plus</i> , 2020 , 4, e10348	3.9	2
229	Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017. <i>Osteoporosis International</i> , 2020 , 31, 1299-1304	5.3	18
228	Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed. <i>Bone</i> , 2020 , 134, 115287	4.7	6
227	T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial 2020 , 29,		1
226	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE. <i>Endocrine Practice</i> , 2020 , 26, 564-570	3.2	59
225	Denosumab: Mechanisms and Therapeutic Effects in the Treatment of Osteoporosis. <i>Contemporary Endocrinology</i> , 2020 , 309-322	0.3	
224	Core principles for fracture prevention: North American Consensus from the National Osteoporosis Foundation, Osteoporosis Canada, and Academia Nacional de Medicina de Mexico. <i>Osteoporosis International</i> , 2020 , 31, 2073-2076	5.3	4
223	T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 1333-1342	6.3	18
222	Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict. <i>Osteoporosis International</i> , 2019 , 30, 2401-2406	5.3	4
221	Repeating Vertebral Fracture Assessment: 2019 ISCD Official Position. <i>Journal of Clinical Densitometry</i> , 2019 , 22, 484-488	3.5	9
220	Repeating Measurement of Bone Mineral Density when Monitoring with Dual-energy X-ray Absorptiometry: 2019 ISCD Official Position. <i>Journal of Clinical Densitometry</i> , 2019 , 22, 489-500	3.5	9
219	Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1033-1040	6.3	48
218	Project ECHO: Telehealth to Expand Capacity to Deliver Best Practice Medical Care. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 303-314	2.4	10
217	Challenges in osteoporosis awareness and management: results from a survey of US postmenopausal women. <i>Journal of Drug Assessment</i> , 2019 , 8, 25-31	1.5	16
216	Fractures While Walking Leashed Dogs. <i>JAMA Surgery</i> , 2019 , 154, 1078	5.4	0
215	Detection of Atypical Femur Fractures. <i>Journal of Clinical Densitometry</i> , 2019 , 22, 506-516	3.5	9

214	Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis. <i>American Journal of Medicine</i> , 2019 , 132, e771-e777	2.4	9
213	Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. <i>Journal of Clinical Densitometry</i> , 2019 , 22, 453-471	3.5	112
212	Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 3450-3461	5.6	11
211	Dual-energy X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position. <i>Journal of Clinical Densitometry</i> , 2019 , 22, 501-505	3.5	35
210	Bone Health TeleECHO: a Force Multiplier to Improve the Care of Skeletal Diseases in Underserved Communities. <i>Current Osteoporosis Reports</i> , 2019 , 17, 474-482	5.4	8
209	Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States. <i>JBMR Plus</i> , 2019 , 3, e10192	3.9	49
208	Treated Osteoporosis Is Still Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 605-606	6.3	14
207	Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. <i>Osteoporosis International</i> , 2019 , 30, 45-57	5.3	39
206	One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 419-428	6.3	78
205	The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. <i>Osteoporosis International</i> , 2019 , 30, 71-78	5.3	5
204	Hip fracture trends in the United States, 2002 to 2015. <i>Osteoporosis International</i> , 2018 , 29, 717-722	5.3	132
203	Stop the war on DXA!. <i>Annals of the New York Academy of Sciences</i> , 2018 , 1433, 12-17	6.5	6
202	Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 298-306	6.3	48
201	Consensus on best practice standards for Fracture Liaison Service in the Asia-Pacific region. <i>Archives of Osteoporosis</i> , 2018 , 13, 59	2.9	9
200	Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1407-1416	6.3	44
199	Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1900-1901	6.3	0
198	Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. <i>Archives of Osteoporosis</i> , 2018 , 13, 85	2.9	12
197	Standard Techniques of Bone Mass Measurement in Adults 2018 , 252-259		

196 Strontium Ranelate and Calcitonin **2018**, 573-578

195 New and emerging concepts in the use of denosumab for the treatment of osteoporosis. *Therapeutic Advances in Musculoskeletal Disease*, **2018**, 10, 209-223 3.8 35

194 A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 3183-3193 5.6 118

193 Adverse effects of media reports on the treatment of osteoporosis. *Journal of Endocrinological Investigation*, **2018**, 41, 1359-1364 5.2 17

192 Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide. *Calcified Tissue International*, **2018**, 103, 540-545 3.9 20

191 Romosozumab for the treatment of osteoporosis. *Expert Opinion on Biological Therapy*, **2017**, 17, 255-263 3.4 52

190 Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. *Journal of Bone and Mineral Research*, **2017**, 32, 1481-1485 6.3 17

189 Osteoporosis: Treat-to-Target. *Current Osteoporosis Reports*, **2017**, 15, 103-109 5.4 13

188 Observations following discontinuation of long-term denosumab therapy. *Osteoporosis International*, **2017**, 28, 1723-1732 5.3 125

187 Osteoporosis in Crisis: It's Time to Focus on Fracture. *Journal of Bone and Mineral Research*, **2017**, 32, 1391-1394 6.3 54

186 Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. *American Journal of Medicine*, **2017**, 130, 862.e1-862.e7 2.4 14

185 DXA: 30years and counting: Introduction to the 30th anniversary issue. *Bone*, **2017**, 104, 1-3 4.7 13

184 Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. *Annals of Internal Medicine*, **2017**, 167, 901 8 1

183 Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. *Annals of Internal Medicine*, **2017**, 167, 902 8 3

182 Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients. *Journal of Managed Care & Specialty Pharmacy*, **2017**, 23, 735-744 1.9 10

181 Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations. *Journal of Bone and Mineral Research*, **2017**, 32, 1977-1980 6.3 45

180 The Clinical Utility of Vertebral Fracture Assessment in Predicting Fractures. *Journal of Clinical Densitometry*, **2017**, 20, 304-308 3.5 5

179 Emerging anabolic agents in the treatment of osteoporosis. *Expert Opinion on Emerging Drugs*, **2017**, 22, 247-257 3.7 13

178	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 3-10	6.3	94
177	Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. <i>Osteoporosis International</i> , 2017 , 28, 1-19	5.3	245
176	Telementoring: a novel approach to reducing the osteoporosis treatment gap. <i>Osteoporosis International</i> , 2017 , 28, 407-411	5.3	12
175	Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis. <i>Journal of the Endocrine Society</i> , 2017 , 1, 1428-1434	0.4	10
174	Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017 , 23, 461-471	1.9	31
173	Bone Health TeleECHO for Orthopedists and Rheumatologists 2017 , 7,		2
172	Romosozumab Treatment in Postmenopausal Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2016 , 375, 1532-1543	59.2	725
171	Clinical Vignettes: Using Non-BMD Measurements in Clinical Practice. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2016 , 14, 50-54	2.5	2
170	Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population. <i>Clinical Therapeutics</i> , 2016 , 38, 1074-1080	3.5	6
169	Bone Health ECHO: telementoring to improve osteoporosis care. <i>Women's Health</i> , 2016 , 12, 79-81	3	14
168	Best Practices for Dual-Energy X-ray Absorptiometry Measurement and Reporting: International Society for Clinical Densitometry Guidance. <i>Journal of Clinical Densitometry</i> , 2016 , 19, 127-40	3.5	131
167	Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1353-63	5.6	42
166	Vertebral Fractures: Clinical Importance and Management. <i>American Journal of Medicine</i> , 2016 , 129, 2211-10	2.1	139
165	Integrated Clinical View on Long-Term Management of Patients with Osteoporosis 2016 , 309-320		
164	High Cardiorespiratory Fitness Is Associated with Reduced Risk of Low Bone Density in Postmenopausal Women. <i>Journal of Women's Health</i> , 2016 , 25, 1073-1080	3	7
163	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2016 , 22, 1111-8	3.2	115
162	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. <i>Endocrine Practice</i> , 2016 , 22, 1-42	3.2	314
161	A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement. <i>European Geriatric Medicine</i> , 2016 , 7, 519-525	3	6

160	Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 681-9	5.5	27
159	Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint. <i>Journal of Clinical Densitometry</i> , 2016 , 19, 485-491	3.5	5
158	A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1429-39	6.3	40
157	The Pathophysiology and Treatment of Osteoporosis. <i>Clinical Therapeutics</i> , 2015 , 37, 1837-50	3.5	149
156	A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1335-42	5.6	80
155	Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors. <i>Climacteric</i> , 2015 , 18 Suppl 2, 39-46	3.1	7
154	FRI0289 Denosumab Treatment in Postmenopausal Women with Osteoporosis for Up to 9 Years: Results Through Year 6 of the Freedom Extension. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 529.2-530 ²⁻⁴		3
153	The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder. <i>Current Opinion in Nephrology and Hypertension</i> , 2015 , 24, 324-9	3.5	7
152	Firearm-related injury and death in the United States. <i>Annals of Internal Medicine</i> , 2015 , 163, 323-4	8	
151	Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. <i>International Journal of Women's Health</i> , 2015 , 7, 565-80	2.8	31
150	Denosumab for the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 461-70	5.5	66
149	Sclerostin and skeletal health. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2015 , 16, 149-56	10.5	23
148	Skeletal Imaging in Primary Hyperparathyroidism 2015 , 447-454		3
147	Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3580-94	5.6	227
146	Update on romosozumab : a humanized monoclonal antibody to sclerostin. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 697-707	5.4	26
145	Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. <i>Journal of Clinical Densitometry</i> , 2014 , 17, 490-5	3.5	14
144	Bone density testing: science, the media, and patient care. <i>Current Osteoporosis Reports</i> , 2014 , 12, 227-9	5.4	6
143	Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength. <i>Journal of Bone and Joint Surgery - Series A</i> , 2014 , 96, e90	5.6	29

142	SAT0487 Denosumab (DMAB) Effect on Bone Histology and Histomorphometry in Men with Low Bone Mineral Density (BMD). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 769.2-769	2.4	
141	SAT0463 Effect of Eight Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Five-Year Results from the Freedom Extension. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 761.2-761	2.4	
140	Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 281-91	3.8	14
139	Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2014 , 6, 48-57	3.8	87
138	Imaging technologies for assessment of skeletal health in men. <i>Current Osteoporosis Reports</i> , 2013 , 11, 1-10	5.4	7
137	Goal-directed treatment of osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 433-8	6.3	47
136	Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. <i>American Journal of Medicine</i> , 2013 , 126, 13-20	2.4	326
135	Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 28-32	3.5	58
134	Osteoporosis update from the 2012 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 584-600	3.5	3
133	Monoclonal antibodies for the treatment of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 183-96	5.4	14
132	Treat-to-target for osteoporosis: is now the time?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 946-53	5.6	51
131	Evaluation of the Patient at Risk for Osteoporosis 2013 , 1481-1504		2
130	Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 1519-28	5.6	79
129	Bone density measurement and assessment of fracture risk. <i>Clinical Obstetrics and Gynecology</i> , 2013 , 56, 667-76	1.7	10
128	Skeletal health in long-duration astronauts: nature, assessment, and management recommendations from the NASA Bone Summit. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1243-55	6.3	97
127	Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. <i>Menopause</i> , 2013 , 20, 130-7	2.5	30
126	Is it time for physicians to focus on the public health threat of gun violence?. <i>Annals of Internal Medicine</i> , 2013 , 158, 851-2	8	
125	Suicide, guns, and public policy. <i>American Journal of Public Health</i> , 2013 , 103, 27-31	5.1	53

124	Suicide affects all of us. <i>Lancet, The</i> , 2012 , 379, 2316-8	40	6
123	Benefits and risks of bisphosphonate therapy for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2272-82	5.6	190
122	A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3161-9	5.6	138
121	Bone density testing intervals and common sense. <i>Current Osteoporosis Reports</i> , 2012 , 10, 217-20	5.4	6
120	More bone density testing is needed, not less. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 739-42	6.3	25
119	Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 1480-6	6.3	105
118	Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2799-808	5.6	73
117	Preventing fractures in diabetic dialysis patients. <i>International Journal of Endocrinology and Metabolism</i> , 2012 , 10, 640-1	1.8	1
116	Osteoporosis update from the 2010 santa fe bone symposium. <i>Journal of Clinical Densitometry</i> , 2011 , 14, 1-21	3.5	8
115	Safety of long-term bisphosphonate therapy for the management of osteoporosis. <i>Drugs</i> , 2011 , 71, 791-814	3.4	59
114	New targets for intervention in the treatment of postmenopausal osteoporosis. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 631-8	8.1	87
113	Official Positions for FRAX [®] Bone Mineral Density and FRAX [®] simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX [®] . <i>Journal of Clinical Densitometry</i> , 2011 , 14, 226-36	3.5	34
112	FRAX [®] Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2011 , 14, 223-5	3.5	15
111	Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. <i>Drug, Healthcare and Patient Safety</i> , 2011 , 3, 79-91	1.6	26
110	The role of risk communication in the care of osteoporosis. <i>Current Osteoporosis Reports</i> , 2011 , 9, 141-8	5.4	9
109	Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 117-27	5.4	32
108	Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX [®] . Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX [®] in clinical practice. <i>Journal of Clinical Densitometry</i> , 2011 , 14, 171-80	3.5	71
107	Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 394-402	5.6	111

106	A piece of my mind. Time to reconsider. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1070-1	27.4	2
105	In the clinic. Osteoporosis. <i>Annals of Internal Medicine</i> , 2011 , 155, ITC1-1-15; quiz ITC1-16	8	12
104	New and emerging therapies for osteoporosis. <i>Journal of Osteoporosis</i> , 2010 , 2010, 318320	2.8	3
103	Bisphosphonates for the treatment of osteoporosis: insights for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2010 , 1, 115-28	4.9	62
102	Clinical use of denosumab for the treatment for postmenopausal osteoporosis. <i>Current Medical Research and Opinion</i> , 2010 , 26, 2807-12	2.5	11
101	Management of skeletal health in patients with asymptomatic primary hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2010 , 13, 324-34	3.5	15
100	2009 Santa Fe Bone symposium. <i>Journal of Clinical Densitometry</i> , 2010 , 13, 1-9	3.5	6
99	International Society for Clinical Densitometry official positions: Asia-Pacific Region consensus. <i>Journal of Clinical Densitometry</i> , 2010 , 13, 346-51	3.5	18
98	Treatment of osteoporosis with denosumab. <i>Maturitas</i> , 2010 , 66, 182-6	5	39
97	Efficacy and safety of monthly ibandronate in men with low bone density. <i>Bone</i> , 2010 , 46, 970-6	4.7	71
96	Risk communication and shared decision making in the care of patients with osteoporosis. <i>Journal of Clinical Densitometry</i> , 2010 , 13, 335-45	3.5	35
95	Denosumab--an emerging treatment for postmenopausal osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 467-76	5.4	10
94	Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. <i>Core Evidence</i> , 2010 , 4, 13-23	4.9	6
93	Algorithm for the management of osteoporosis. <i>Southern Medical Journal</i> , 2010 , 103, 1009-15; quiz 1016	6.6	13
92	Fracture Risk Assessment in Clinical Practice: T-scores, FRAX, and Beyond. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2010 , 8, 101-112	2.5	5
91	Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis. <i>Current Osteoporosis Reports</i> , 2010 , 8, 15-22	5.4	24
90	Bone densitometry and vertebral fracture assessment. <i>Current Osteoporosis Reports</i> , 2010 , 8, 123-30	5.4	52
89	Monitoring pharmacological therapy for osteoporosis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2010 , 11, 261-73	10.5	8

88	The evolution of fracture risk estimation. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2098-100	6.3	6
87	Lasofosifene for the prevention and treatment of postmenopausal osteoporosis. <i>Therapeutics and Clinical Risk Management</i> , 2009 , 5, 817-27	2.9	12
86	Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 351-65	5.6	257
85	Managing osteoporosis: challenges and strategies. <i>Cleveland Clinic Journal of Medicine</i> , 2009 , 76, 457-66	2.8	23
84	Pharmacologic therapy to reduce fracture risk: comment on the clinical practice guidelines of the ACP. <i>Nature Reviews Rheumatology</i> , 2009 , 5, 120-1	8.1	
83	Denosumab in postmenopausal osteoporosis: what the clinician needs to know. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2009 , 1, 13-26	3.8	9
82	Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 171-80	5.6	79
81	Denosumab for joints and bones. <i>Current Rheumatology Reports</i> , 2009 , 11, 196-201	4.9	9
80	Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1643-6	6.3	46
79	Safety of bisphosphonates in the treatment of osteoporosis. <i>American Journal of Medicine</i> , 2009 , 122, S22-32	2.4	74
78	Denosumab for the treatment of postmenopausal osteoporosis. <i>Women's Health</i> , 2009 , 5, 15-22	3	5
77	Is denosumab better than alendronate in the treatment of osteoporosis?. <i>Nature Clinical Practice Rheumatology</i> , 2009 , 5, 72-3		2
76	Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. <i>Journal of Women's Health</i> , 2009 , 18, 1615-26	3	40
75	Emerging drugs for postmenopausal osteoporosis. <i>Expert Opinion on Emerging Drugs</i> , 2009 , 14, 129-44	3.7	20
74	The official positions of the International Society for Clinical Densitometry: perceptions and commentary. <i>Journal of Clinical Densitometry</i> , 2009 , 12, 267-71	3.5	24
73	Denosumab update. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 369-73	5.3	33
72	Kyphosis and vertebral fractures: what do we know now?. <i>Aging Health</i> , 2009 , 5, 483-487		1
71	Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis. <i>Endocrine Practice</i> , 2009 , 15, 573-9	3.2	10

70	New guidelines for the prevention and treatment of osteoporosis. <i>Southern Medical Journal</i> , 2009 , 102, 175-9	0.6	22
69	Phytoestrogens and their role in the management of postmenopausal osteoporosis. <i>Southern Medical Journal</i> , 2009 , 102, 111-2	0.6	1
68	Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. <i>IDrugs: the Investigational Drugs Journal</i> , 2009 , 12, 799-809		18
67	Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2008 , 11, 75-91	3.5	344
66	Prevention and treatment of postmenopausal osteoporosis. <i>Obstetrics and Gynecology Clinics of North America</i> , 2008 , 35, 301-15, ix	3.3	34
65	Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. <i>Bone</i> , 2008 , 43, 222-229	4.7	408
64	Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. <i>Clinical Therapeutics</i> , 2008 , 30, 605-21	3.5	29
63	A clinician's perspective on the use of zoledronic acid in the treatment of postmenopausal osteoporosis. <i>Journal of Clinical Densitometry</i> , 2008 , 11, 478-84	3.5	5
62	Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2008 , 11, 188-206	3.5	55
61	Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. <i>Journal of Clinical Densitometry</i> , 2008 , 11, 351-9	3.5	43
60	Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2008 , 11, 163-87	3.5	275
59	Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2008 , 11, 123-62	3.5	326
58	Common mistakes in the clinical use of bone mineral density testing. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 667-74		44
57	Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. <i>Southern Medical Journal</i> , 2008 , 101, 735-9	0.6	23
56	Denosumab: an investigational drug for the management of postmenopausal osteoporosis. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 645-53	4.4	19
55	Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 6-16	6.3	160
54	Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 525-35	6.3	176
53	Tumor-induced osteomalacia: lessons learned. <i>Arthritis and Rheumatism</i> , 2008 , 58, 773-7		37

52	Do Phytoestrogens Have a Role in the Management of Postmenopausal Osteoporosis?. <i>Southern Medical Journal</i> , 2008 , 101, 2	0.6	
51	Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 1663-72	5.9	23
50	Diagnostic agreement at the total hip using different DXA systems and the NHANES III database. <i>Journal of Clinical Densitometry</i> , 2007 , 10, 132-7	3.5	11
49	A review of strontium ranelate and its effect on DXA scans. <i>Journal of Clinical Densitometry</i> , 2007 , 10, 113-9	3.5	33
48	Standards and guidelines for technologists performing central dual-energy X-ray absorptiometry. <i>Journal of Clinical Densitometry</i> , 2007 , 10, 189-95	3.5	12
47	Vertebral Fracture Assessment by dual-energy X-ray absorptiometry: insurance coverage issues in the United States. A White Paper of the International Society for Clinical Densitometry. <i>Journal of Clinical Densitometry</i> , 2007 , 10, 227-38	3.5	16
46	Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. <i>Expert Opinion on Drug Safety</i> , 2007 , 6, 663-72	4.1	37
45	Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 1832-41	6.3	239
44	Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4671-7	5.6	70
43	Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. <i>Bone</i> , 2007 , 40, 843-51	4.7	49
42	Long dosing intervals in the treatment of postmenopausal osteoporosis. <i>Current Medical Research and Opinion</i> , 2007 , 23, 2617-25	2.5	7
41	Medications don't work if patients don't take them. <i>Southern Medical Journal</i> , 2007 , 100, 1190-1	0.6	2
40	Denosumab: a promising drug for the prevention and treatment of osteoporosis. <i>Women's Health</i> , 2006 , 2, 517-25	3	9
39	Clinical review: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4215-22	5.6	140
38	RANK ligand inhibition with denosumab for the management of osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2006 , 6, 1041-50	5.4	38
37	Is it ethical to use placebos in osteoporosis trials?. <i>Journal of Clinical Densitometry</i> , 2006 , 9, 274-80	3.5	3
36	Vertebral fracture assessment: the 2005 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2006 , 9, 37-46	3.5	91
35	Standards for performing DXA in individuals with secondary causes of osteoporosis. <i>Journal of Clinical Densitometry</i> , 2006 , 9, 47-57	3.5	31

34	DXA quality matters. <i>Journal of Clinical Densitometry</i> , 2006 , 9, 388-92	3.5	56
33	Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2006 , 9, 4-14	3.5	116
32	Denosumab in postmenopausal women with low bone mineral density. <i>New England Journal of Medicine</i> , 2006 , 354, 821-31	59.2	931
31	Bone density testing in clinical practice. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2006 , 50, 586-95		31
30	Prevention of osteoporotic fractures. <i>Aging Health</i> , 2006 , 2, 649-659		
29	Official positions of the International Society for Clinical Densitometry. <i>Osteoporosis International</i> , 2006 , 17, 1700-1	5.3	14
28	Uses and misuses of quantitative ultrasonography in managing osteoporosis. <i>Cleveland Clinic Journal of Medicine</i> , 2006 , 73, 742-6, 749-52	2.8	19
27	Skeletal health prognostications. <i>Southern Medical Journal</i> , 2006 , 99, 105-6	0.6	
26	Augmentation procedures for osteoporotic vertebral fractures--an ongoing experiment or emerging standard of care?. <i>Southern Medical Journal</i> , 2006 , 99, 449-50	0.6	2
25	Is alendronate therapy cost-effective for postmenopausal osteopenia?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2005 , 1, 74-5		1
24	Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. <i>Journal of Clinical Densitometry</i> , 2005 , 8, 371-8	3.5	215
23	Response to "The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry," by John A. Kanis et al. <i>Journal of Clinical Densitometry</i> , 2005 , 8, 143-4	3.5	11
22	Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 195-201	6.3	90
21	Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 962-70	6.3	247
20	Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1315-22	6.3	230
19	Review of guidelines for bone mineral density testing and treatment of osteoporosis. <i>Current Osteoporosis Reports</i> , 2005 , 3, 75-83	5.4	44
18	Update on bone density testing. <i>Current Osteoporosis Reports</i> , 2005 , 3, 136-42	5.4	16
17	Premenopausal bone health assessment. <i>Current Rheumatology Reports</i> , 2005 , 7, 46-52	4.9	21

16	Update on osteoporosis. <i>Women's Health</i> , 2005 , 1, 23-5	3	
15	Clinical use of serum and urine bone markers in the management of osteoporosis. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1015-26	2.5	60
14	Update on bone density testing. <i>Current Osteoporosis Reports</i> , 2005 , 3, 136-142	5.4	
13	Special report on the official positions of the International Society for Clinical Densitometry. <i>Osteoporosis International</i> , 2004 , 15, 779-84	5.3	55
12	Management of osteoporosis. <i>Clinical and Molecular Allergy</i> , 2004 , 2, 9	3.7	17
11	Recommendations regarding individuals in whom bone densitometry should be performed: comment on the article by van Staa et al. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2715-6		
10	Official positions of the International Society for Clinical Densitometry. <i>Journal of Clinical Densitometry</i> , 2004 , 7, 1-6	3.5	215
9	Impact of using the ultradistal radius region of interest on diagnostic classification. <i>Journal of Clinical Densitometry</i> , 2004 , 7, 143-52	3.5	7
8	Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. <i>Journal of Clinical Densitometry</i> , 2004 , 7, 51-64	3.5	88
7	Official positions of the international society for clinical densitometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3651-5	5.6	211
6	Official positions of the International Society for Clinical Densitometry. <i>Southern Medical Journal</i> , 2004 , 97, 107-10	0.6	13
5	Nonresponders to osteoporosis therapy. <i>Journal of Clinical Densitometry</i> , 2003 , 6, 307-14	3.5	76
4	Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. <i>Clinical Therapeutics</i> , 2002 , 24, 1871-86	3.5	146
3	Monitoring Therapy for Osteoporosis 227-238		
2	The current role of telehealth in the management of patients with osteoporosis. <i>Expert Review of Endocrinology and Metabolism</i> ,	4.1	0
1	The role of osteoanabolic agents in the management of patients with osteoporosis. <i>Postgraduate Medicine</i> , 1-11	3.7	1